{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:13:55Z","timestamp":1788754435994,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite global consensus on the management of acute coronary syndrome (ACS), implementation of strategies to improve adherence of guideline-directed medical therapy (GDMT) remains sub-optimal, especially in developing countries. Thus, we aimed to assess the effect of clinical pharmacist-led clinical audit to improve the compliance of discharge prescriptions in patients admitted with ACS. It is a prospective clinical audit of ACS patients which was carried out for 12\u00a0months. The discharge prescriptions were audited by clinical pharmacists for the appropriateness in the usage of statins, dual antiplatelet therapy (DAPT), beta-blockers, and angiotensin-converting enzyme inhibitors (ACE-I)\/angiotensin receptor blocker (ARB). A feedback report was presented every month to the cardiologists involved in the patient care, and the trend in the adherence to GDMT was analyzed over 12\u00a0months.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The discharge prescriptions of 1072 ACS patients were audited for the justifiable and non-justifiable omissions of mandated drugs. The first-month audit revealed unreasonable omissions of DAPT, statin, ACE-I\/ARB, and beta-blockers in 1%, 0%, 14%, and 11% respectively, which reduced to nil by the end of the 11th month of the audit\u2013feedback program. This improvement remained unchanged until the end of the 12th month.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The study revealed that periodic clinical audit significantly improves adherence to GDMT in patients admitted with ACS.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-021-00237-7","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T08:02:56Z","timestamp":1641974576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Implementation of clinical audit to improve adherence to guideline-recommended therapy in acute coronary syndrome"],"prefix":"10.1186","volume":"74","author":[{"given":"Nimmy Elizabeth","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashiq Ahamed","family":"Shukkoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramasamy","family":"Palanimuthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamilarasu","family":"Kaliappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendiran","family":"Gopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"issue":"24","key":"237_CR1","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr et al (2014) 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64(24):e139\u2013e228","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"237_CR2","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.ihj.2017.03.006","volume":"69","author":"S Guha","year":"2017","unstructured":"Guha S, Sethi R, Ray S, Bahl VK, Shanmugasundaram S, Kerkar P et al (2017) Cardiological Society of India: position statement for the management of ST elevation myocardial infarction in India. Indian Heart J 69(Suppl 1):S63\u2013S97","journal-title":"Indian Heart J"},{"issue":"1","key":"237_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12872-016-0388-y","volume":"16","author":"MM Bhagwat","year":"2016","unstructured":"Bhagwat MM, Woods JA, Dronavalli M, Hamilton SJ, Thompson SC (2016) Evidence-based interventions in primary care following acute coronary syndrome in Australia and New Zealand: a systematic scoping review. BMC Cardiovasc Disord 16(1):214","journal-title":"BMC Cardiovasc Disord"},{"issue":"4","key":"237_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jacc.2010.05.008","volume":"56","author":"MT Roe","year":"2010","unstructured":"Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D et al (2010) Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol 56(4):254\u2013263","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"237_CR5","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.4244\/EIJV8I10A176","volume":"8","author":"P Tobbia","year":"2013","unstructured":"Tobbia P, Brodie BR, Witzenbichler B, Metzger C, Guagliumi G, Yu J et al (2013) Adverse event rates following primary PCI for STEMI at US and non-US hospitals: 3-year analysis from the HORIZONS-AMI trial. EuroIntervention 8(10):1134\u20131142","journal-title":"EuroIntervention"},{"key":"237_CR6","doi-asserted-by":"publisher","first-page":"f6544","DOI":"10.1136\/bmj.f6544","volume":"347","author":"K Jones","year":"2013","unstructured":"Jones K, Saxon L, Cunningham W, Adams P, Guideline Development Group (2013) Secondary prevention for patients after a myocardial infarction: summary of updated NICE guidance. BMJ 347:f6544","journal-title":"BMJ"},{"issue":"6","key":"237_CR7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/hrt.2003.020321","volume":"90","author":"KA Fox","year":"2004","unstructured":"Fox KA (2004) Management of acute coronary syndromes: an update. Heart 90(6):698\u2013706","journal-title":"Heart"},{"issue":"7","key":"237_CR8","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/S0735-1097(02)02336-7","volume":"40","author":"E Braunwald","year":"2002","unstructured":"Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS et al (2002) American College of Cardiology; American Heart Association. Committee on the Management of Patients with Unstable Angina. ACC\/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction\u2014summary article: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40(7):1366\u20131374","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"237_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H et al (2018) ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119\u2013177","journal-title":"Eur Heart J"},{"issue":"3","key":"237_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/2048872614548602","volume":"4","author":"AD Simms","year":"2015","unstructured":"Simms AD, Weston CF, West RM, Hall AS, Batin PD, Timmis A et al (2015) Mortality and missed opportunities along the pathway of care for ST-elevation myocardial infarction: a national cohort study. Eur Heart J Acute Cardiovasc Care 4(3):241\u2013253","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"9622","key":"237_CR11","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S0140-6736(08)60623-6","volume":"371","author":"D Xavier","year":"2008","unstructured":"Xavier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS et al (2008) CREATE registry investigators. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet 371(9622):1435\u20131442","journal-title":"Lancet"},{"issue":"8","key":"237_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1136\/hrt.2009.188607","volume":"96","author":"P Bramlage","year":"2010","unstructured":"Bramlage P, Messer C, Bitterlich N, Pohlmann C, Cuneo A, Stammwitz E et al (2010) The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart 96(8):604\u2013609","journal-title":"Heart"},{"issue":"1","key":"237_CR13","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.18549\/PharmPract.2019.1.1372","volume":"17","author":"OA Nassr","year":"2019","unstructured":"Nassr OA, Forsyth P, Johnson CF (2019) Evaluation of discharge prescriptions for secondary prevention in patients with acute coronary syndromes in Iraq. Pharm Pract (Granada) 17(1):1372","journal-title":"Pharm Pract (Granada)"},{"issue":"1","key":"237_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12872-019-1101-8","volume":"19","author":"V Kyt\u00f6","year":"2019","unstructured":"Kyt\u00f6 V, Prami T, Khanfir H, Hasvold P, Reissell E, Airaksinen J (2019) Usage of PCI and long-term cardiovascular risk in post-myocardial infarction patients: a nationwide registry cohort study from Finland. BMC Cardiovasc Disord 19(1):123","journal-title":"BMC Cardiovasc Disord"},{"issue":"12","key":"237_CR15","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.amjcard.2016.08.065","volume":"118","author":"RC Makam","year":"2016","unstructured":"Makam RC, Erskine N, McManus DD, Lessard D, Gore JM, Yarzebski J et al (2016) Decade-long trends (2001 to 2011) in the use of evidence-based medical therapies at the time of hospital discharge for patients surviving acute myocardial infarction. Am J Cardiol 118(12):1792\u20131797","journal-title":"Am J Cardiol"},{"issue":"3","key":"237_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.18553\/jmcp.2008.14.3.271","volume":"14","author":"HY Lee","year":"2008","unstructured":"Lee HY, Cooke CE, Robertson TA (2008) Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 14(3):271\u2013280","journal-title":"J Manag Care Pharm"},{"issue":"6","key":"237_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/0003319710394163","volume":"62","author":"I Al-Zakwani","year":"2011","unstructured":"Al-Zakwani I, Zubaid M, Panduranga P, Rashed W, Sulaiman K, Almahmeed W et al (2011) Medication use pattern and predictors of optimal therapy at discharge in 8176 patients with acute coronary syndrome from 6 Middle Eastern countries: data from the gulf registry of acute coronary events. Angiology 62(6):447\u2013454","journal-title":"Angiology"},{"issue":"6","key":"237_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1365-2710.2008.00950.x","volume":"33","author":"NS Vermeer","year":"2008","unstructured":"Vermeer NS, Bajorek BV (2008) Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice. J Clin Pharm Ther 33(6):591\u2013601","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"237_CR19","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1365-2753.2012.01894.x","volume":"19","author":"YW Kassab","year":"2013","unstructured":"Kassab YW, Hassan Y, Aziz NA, Akram H, Ismail O (2013) Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice. J Eval Clin Pract 19(4):658\u2013663","journal-title":"J Eval Clin Pract"},{"key":"237_CR20","first-page":"167","volume":"12","author":"HJ Byeon","year":"2016","unstructured":"Byeon HJ, Yang YM, Choi EJ (2016) Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea. Ther Clin Risk Manag 12:167\u2013175","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"237_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.18553\/jmcp.2008.14.3.312","volume":"14","author":"BJ Quilliam","year":"2008","unstructured":"Quilliam BJ (2008) Suboptimal utilization of secondary drug prevention in acute coronary syndrome: measurement issues and managed care opportunities. J Manag Care Pharm 14(3):312\u2013315","journal-title":"J Manag Care Pharm"},{"issue":"6","key":"237_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.sapharm.2017.06.004","volume":"14","author":"MS El Hajj","year":"2018","unstructured":"El Hajj MS, Jaam MJ, Awaisu A (2018) Effect of pharmacist care on medication adherence and cardiovascular outcomes among patients post-acute coronary syndrome: a systematic review. Res Social Adm Pharm 14(6):507\u2013520","journal-title":"Res Social Adm Pharm"},{"issue":"4","key":"237_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jsps.2020.02.009","volume":"28","author":"AM Jabri","year":"2020","unstructured":"Jabri AM, Assad HC, Al-Jumaili AA (2020) Pharmacist role to enhance the prescribing of hospital discharge medications for patients after heart attack. Saudi Pharm J 28(4):473\u2013479","journal-title":"Saudi Pharm J"},{"issue":"2","key":"237_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/jcpt.12027","volume":"38","author":"Y Hassan","year":"2013","unstructured":"Hassan Y, Kassab Y, Abd Aziz N, Akram H, Ismail O (2013) The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge. J Clin Pharm Ther 38(2):97\u2013100","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"237_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.5527\/wjn.v3.i4.249","volume":"3","author":"P Esposito","year":"2014","unstructured":"Esposito P, Dal Canton A (2014) Clinical audit, a valuable tool to improve quality of care: general methodology and applications in nephrology. World J Nephrol 3(4):249\u2013255","journal-title":"World J Nephrol"},{"issue":"7","key":"237_CR26","doi-asserted-by":"publisher","first-page":"e0219676","DOI":"10.1371\/journal.pone.0219676","volume":"14","author":"R Marcucci","year":"2019","unstructured":"Marcucci R, Patti G, Calabr\u00f2 P, Gori AM, Grossi G, Cirillo P et al (2019) Antiplatelet treatment in acute coronary syndrome patients: real-world data from the START-Antiplatelet Italian Registry. PLoS ONE 14(7):e0219676","journal-title":"PLoS ONE"},{"issue":"11","key":"237_CR27","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/clc.22038","volume":"35","author":"MJ Kim","year":"2012","unstructured":"Kim MJ, Jeon DS, Gwon HC, Kim SJ, Chang K, Kim HS et al (2012) Korean MUSTANG Investigators. Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea. Clin Cardiol 35(11):700\u2013706","journal-title":"Clin Cardiol"},{"key":"237_CR28","doi-asserted-by":"publisher","first-page":"478597","DOI":"10.1155\/2013\/478597","volume":"2013","author":"HT Ong","year":"2013","unstructured":"Ong HT, Ong LM, Ho JJ (2013) Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in patients at high risk of cardiovascular events: a meta-analysis of 10 randomised placebo-controlled trials. ISRN Cardiol. 2013:478597","journal-title":"ISRN Cardiol."},{"issue":"2","key":"237_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/CIRCOUTCOMES.113.000422","volume":"7","author":"KR Bainey","year":"2014","unstructured":"Bainey KR, Armstrong PW, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED et al (2014) Use of renin\u2013angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program. Circ Cardiovasc Qual Outcomes 7(2):227\u2013235","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"237_CR30","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2174\/1570161114666160226150336","volume":"14","author":"MS El-Hajj","year":"2016","unstructured":"El-Hajj MS, Saad A, Al-Suwaidi J, Al-Marridi WZ, Elkhalifa DH, Mohamed AA et al (2016) Utilization of evidence-based secondary prevention medications at the time of discharge in patients with acute coronary syndrome (ACS) in Qatar. Curr Vasc Pharmacol 14(4):394\u2013403","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"237_CR31","doi-asserted-by":"publisher","first-page":"e001173","DOI":"10.1136\/openhrt-2019-001173","volume":"7","author":"MG Nhat","year":"2020","unstructured":"Nhat MG, Hai HN, Ngoc-Hoa C (2020) Renal kinetics in acute heart failure. Open Heart. 7(1):e001173","journal-title":"Open Heart."},{"issue":"11","key":"237_CR32","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.21037\/jtd.2017.10.25","volume":"9","author":"S Noble","year":"2017","unstructured":"Noble S, Roffi M (2017) Routine beta-blocker administration following acute myocardial infarction: why still an unsolved issue? J Thorac Dis 9(11):4191\u20134194","journal-title":"J Thorac Dis"},{"issue":"1","key":"237_CR33","doi-asserted-by":"publisher","first-page":"e018271","DOI":"10.1136\/bmjopen-2017-018271","volume":"8","author":"T Nguyen","year":"2018","unstructured":"Nguyen T, Nguyen HQ, Widyakusuma NN, Nguyen TH, Pham TT, Taxis K (2018) Enhancing prescribing of guideline-recommended medications for ischaemic heart diseases: a systematic review and meta-analysis of interventions targeted at healthcare professionals. BMJ Open 8(1):e018271","journal-title":"BMJ Open"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-021-00237-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-021-00237-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-021-00237-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T08:21:55Z","timestamp":1641975715000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-021-00237-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["237"],"URL":"https:\/\/doi.org\/10.1186\/s43044-021-00237-7","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]},"assertion":[{"value":"8 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients were included after written consent was signed by the patients. The institutional human ethics committee of PSG Institute of Medical Sciences and Research gave approval number (20\/135).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares that there are no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}